Jury still out on saxagliptin safety

Answer: A recent clinical trial reported a small increase in the number of hospitalisations for heart failure among patients taking saxagliptin compared with those on placebo. 1 

The US Food and Drug Administration (FDA) is currently investigating data from the trial, but no change in practice is suggested at present. 2

The SAVOR-TIMI 53 postmarketing trial found 3.5% of patients taking saxagliptin were hospitalised for heart failure compared with 2.8% of those on placebo (HR 1